Ofatumumab
Brand Names: Kesimpta
Methodology & AI Transparency ⓘ
Ofatumumab Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Registered across 20 mg/.4mL Injection, Solution under FDA code 0078-1007 (manufactured/labeled by Novartis Pharmaceuticals Corporation), Ofatumumab delivers subcutaneous-route cd20-directed cytolytic antibody pharmacotherapy tailored to patient-specific diagnostic criteria.
- 2 Real-world patient consensus: Real-world cohort score of 94% across 21 de-identified Ofatumumab entries.
- 3 Typical cash cost range: Public pharmacy ledger: $185.00 low cash benchmark vs. $453.25 chain retail average ($22647.5186/unit CMS NADAC).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Ofatumumab: nausea (7.4%), headache (7.6%), dizziness (5.3%).
Ask our AI Specialists anything about Ofatumumab
Ofatumumab Mechanism, CYP450 Pathways & DailyMed Monograph
Registered across 20 mg/.4mL Injection, Solution under FDA code 0078-1007 (manufactured/labeled by Novartis Pharmaceuticals Corporation), Ofatumumab delivers subcutaneous-route cd20-directed cytolytic antibody pharmacotherapy tailored to patient-specific diagnostic criteria.
Biochemical activity of Ofatumumab reflects cd20-directed cytolytic antibody pathway engagement after subcutaneous-route dosing (20 mg/.4mL Injection, Solution, manufactured/labeled by Novartis Pharmaceuticals Corporation, NDC 0078-1007), supporting titratable maintenance pharmacotherapy.
Systemic exposure to Ofatumumab reflects Complete (~100%) parenteral systemic delivery for Ofatumumab (20 mg/.4mL Injection, Solution) absorption kinetics and systemic clearance of ofatumumab integrates hepatic phase ii conjugation with renal filtration, sustaining receptor engagement across a Elimination kinetics span 11 to 21 hours per Ofatumumab clinical pharmacology half-life window (rapid intravascular/parenteral onset within 15–45 minutes after ofatumumab administration response profile).
Dosing protocols (20 mg/.4mL Injection, Solution or 20 mg or 4mL) balance efficacy (94.00% patient satisfaction across 21 logs) against headache (7.6% of reports), nausea (7.4% of reports), dizziness (5.3% of reports), with strict avoidance in previous anaphylactoid or exfoliative reaction attributed to ofatumumab; clinical scenarios where cd20-directed cytolytic antibody exposure from ofatumumab poses unacceptable risk.
Verify medication reconciliation lists so Ofatumumab is not inadvertently duplicated with another cd20-directed cytolytic antibody.
Botanical enzyme modulators may alter oral first-pass exposure of Ofatumumab; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Ofatumumab
- Clinical scenarios where cd20-directed cytolytic antibody exposure from Ofatumumab poses unacceptable risk
Logged Side-Effect Incidence (21 Reports)
Ofatumumab Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Ofatumumab)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety experience with continued exposure to ofatumumab in patients with: What a 1,650-Participant Study Found In patients with up to 3.5 years' exposure, ofatumumab was well tolerated, with no new safety risks identified. Multiple sclerosis (Houndmills, Basingstoke, England) • 2022-09-15 • Phase III Randomized Trial | N = 1,650 | 90/100 | PMID 35229668 ↗ |
| New Insights on A phase 3, randomized study of ofatumumab combined with bendamustine in: What a 346-Participant Study Found The study did not meet its primary end-point. British journal of haematology • 2021-06-15 • Phase III Randomized Trial | N = 346 | 87/100 | PMID 33973233 ↗ |
Ofatumumab Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $22647.5186/unit (~$679425.56/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 21 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Ofatumumab Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Ofatumumab RxNorm Concept ID | RXN-00781007-3206 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $22647.5186 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 94.00% Worth It (21 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Ofatumumab Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Ofatumumab integrating DailyMed SPL (2026-07-01), CMS NADAC ($22647.5186/unit), and 21 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Ofatumumab community threads and patient logs by age, biological sex, dosage, and treatment duration.